Zymeworks was a private biopharmaceutical company based in Vancouver, Canada. The company leveraged its novel platforms to design and develop best-in-class bi-specific antibody and ADC treatments. Its lead program, zanidatamab, a bispecific antibody targeting HER2-expressing cancers. In 2017, Zymeworks went public on the NYSE under the ticker ZYME.

Specialty

Solid tumors

Fund name

CTI LSF I

Position

Lead

Board

Director

Investment Date

January 22, 2009

Exit Detail

IPO on the NYSE

Initial Series Round

Series A

Investment Thesis

Zymeworks had two innovative rationale design platforms – Azymetric and Zymelink, for rationale design of antibody-based treatments

Specialty

Fund name

Position

Board

Investment Date

Exit Detail

Initial Series Round

Investment Thesis

Related News

Zymeworks Completes Acquisition of Kairos Therapeutics Creating a Leader in Biologics Drug Discovery and Development

Zymeworks Closes C$3.4M Financing Round and Announces Changes to its Board of Directors

Zymeworks Names Diana Hausman, M.D. Chief Medical Officer

Zymeworks and GSK Enter Second Strategic Collaboration to Develop and Commercialize Bi-Specific Antibodies

Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies

Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium

Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics

Zymeworks Announces Pricing of Initial Public Offering

Zymeworks Announces $61.5 Million Financing to Support the Clinical Development of its Pipeline of Azymetric™ Antibody Therapeutics

Zymeworks Closes C$3.2M Round of Financing

Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration

Phone

Email

Address

Social Media